PE20110931A1 - Pirrolidin-2-onas como ligandos de hdm2 - Google Patents
Pirrolidin-2-onas como ligandos de hdm2Info
- Publication number
- PE20110931A1 PE20110931A1 PE2011000624A PE2011000624A PE20110931A1 PE 20110931 A1 PE20110931 A1 PE 20110931A1 PE 2011000624 A PE2011000624 A PE 2011000624A PE 2011000624 A PE2011000624 A PE 2011000624A PE 20110931 A1 PE20110931 A1 PE 20110931A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrrolidin
- methyl
- indol
- carboxamide
- chlorophenyl
- Prior art date
Links
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- -1 4-METHYLPHENYL Chemical class 0.000 abstract 3
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 3
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRROLIDIN-2-ONA DE FORMULA (I), DONDE V ES C=O, C=S O CH2; X ES S, O, CH2, NH, ENTRE OTROS; Y ES CO, COO, CH2O, CH2CO, ENTRE OTROS; n ES UN ENTERO DE 0 A 3; R1, R2, R3, R4, R5, R7 Y R8 SON H, ALQUILO C1-C20, ALQUENILO C2-C20, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-[(4-CLOROFENIL)METIL]-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(PIRIDIN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-[(4-CLOROFENIL)METIL]-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(TIOFEN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-(4-CLOROFENIL)-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(PIRIDIN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE UNION A LA PROTEINA HDM2 QUE INDUCEN LA APOPTOSIS Y LA INHIBICION DE LA PROLIFERACION Y SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9696408P | 2008-09-15 | 2008-09-15 | |
EP08016236 | 2008-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110931A1 true PE20110931A1 (es) | 2012-01-25 |
Family
ID=40303570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000624A PE20110931A1 (es) | 2008-09-15 | 2009-09-15 | Pirrolidin-2-onas como ligandos de hdm2 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8119623B2 (es) |
EP (1) | EP2346852B1 (es) |
JP (1) | JP5701758B2 (es) |
KR (1) | KR20110063542A (es) |
CN (1) | CN102149708A (es) |
AR (1) | AR073578A1 (es) |
AU (1) | AU2009291155A1 (es) |
BR (1) | BRPI0918603A2 (es) |
CA (1) | CA2736295A1 (es) |
EA (1) | EA201100483A1 (es) |
NZ (1) | NZ591073A (es) |
PE (1) | PE20110931A1 (es) |
TW (1) | TW201011009A (es) |
WO (1) | WO2010028862A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
WO2010051561A1 (en) * | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Compounds for the treatment of osteoporosis and cancers |
EP2480531B1 (en) * | 2009-09-21 | 2014-11-05 | ChemoCentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
WO2012065181A2 (en) * | 2010-11-12 | 2012-05-18 | Dana Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
RS57158B1 (sr) | 2011-03-10 | 2018-07-31 | Daiichi Sankyo Co Ltd | Dispiropirolidinski derivat |
WO2013025939A2 (en) * | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
JP6093770B2 (ja) * | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としての複素環化合物 |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
US9505775B2 (en) | 2012-11-03 | 2016-11-29 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
MX2016006657A (es) | 2013-11-22 | 2016-10-12 | CL BioSciences LLC | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. |
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
DK3424534T3 (da) | 2014-04-15 | 2021-07-26 | Vertex Pharma | Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator |
ES2841308T3 (es) | 2014-05-29 | 2021-07-08 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirrolidina novedoso y aplicación como agonista del receptor de melanocortina |
JP6503386B2 (ja) * | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | MDM2−p53阻害剤としての新しいスピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン化合物および誘導体 |
BR112017002942B1 (pt) | 2014-08-21 | 2022-10-18 | Boehringer Ingelheim International Gmbh | Compostos e derivados de espiro[3h-indol-3,2'- pirrolidin]2(1h)-ona, composição farmacêutica que os compreende, intermediário sintético, uso destes compostos e método para sintetizar o intermediário |
WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
EP3260119B1 (en) | 2015-02-20 | 2023-11-15 | Daiichi Sankyo Company, Limited | Combination method for treating cancer |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
KR20180034466A (ko) | 2015-07-02 | 2018-04-04 | 호리즌 오펀 엘엘씨 | Ado-저항성 시스테아민 유사체 및 그의 용도 |
CA3000063A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
WO2017090743A1 (ja) * | 2015-11-27 | 2017-06-01 | 田辺三菱製薬株式会社 | 新規イミダゾール化合物およびメラノコルチン受容体作動薬としての用途 |
CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
EP3527226A4 (en) | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | POLYTHERAPY METHOD USING MDM2 INHIBITOR AND DNA METHYLTRANSFERASE INHIBITOR |
CN114949228A (zh) | 2017-04-05 | 2022-08-30 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CN114558002A (zh) * | 2022-03-15 | 2022-05-31 | 四川轻化工大学 | 化合物在制备治疗肿瘤药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361759A (en) * | 1963-10-07 | 1968-01-02 | Upjohn Co | 3-(2-pyrrolidinyl)-indoles and method of preparation |
US4219560A (en) * | 1978-04-17 | 1980-08-26 | Sandoz, Inc. | Piperidine and pyrrolidine alcohols |
US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
EP1180513A4 (en) | 1999-04-28 | 2002-07-10 | Takeda Chemical Industries Ltd | CYCLIC AMID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
MX2009000285A (es) * | 2006-06-30 | 2009-06-08 | Schering Corp | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. |
US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
-
2009
- 2009-09-11 TW TW098130660A patent/TW201011009A/zh unknown
- 2009-09-11 AR ARP090103497A patent/AR073578A1/es not_active Application Discontinuation
- 2009-09-15 EP EP09778533.1A patent/EP2346852B1/en active Active
- 2009-09-15 BR BRPI0918603A patent/BRPI0918603A2/pt not_active IP Right Cessation
- 2009-09-15 CA CA2736295A patent/CA2736295A1/en not_active Abandoned
- 2009-09-15 PE PE2011000624A patent/PE20110931A1/es not_active Application Discontinuation
- 2009-09-15 KR KR1020117008667A patent/KR20110063542A/ko not_active Application Discontinuation
- 2009-09-15 WO PCT/EP2009/006670 patent/WO2010028862A1/en active Application Filing
- 2009-09-15 NZ NZ591073A patent/NZ591073A/xx not_active IP Right Cessation
- 2009-09-15 US US12/560,051 patent/US8119623B2/en active Active
- 2009-09-15 AU AU2009291155A patent/AU2009291155A1/en not_active Abandoned
- 2009-09-15 CN CN200980135970XA patent/CN102149708A/zh active Pending
- 2009-09-15 JP JP2011526418A patent/JP5701758B2/ja active Active
- 2009-09-15 EA EA201100483A patent/EA201100483A1/ru unknown
-
2012
- 2012-01-17 US US13/351,914 patent/US9045414B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102149708A (zh) | 2011-08-10 |
US8119623B2 (en) | 2012-02-21 |
EP2346852B1 (en) | 2015-02-25 |
BRPI0918603A2 (pt) | 2017-06-20 |
US9045414B2 (en) | 2015-06-02 |
TW201011009A (en) | 2010-03-16 |
US20120122839A1 (en) | 2012-05-17 |
EP2346852A1 (en) | 2011-07-27 |
WO2010028862A1 (en) | 2010-03-18 |
US20100075949A1 (en) | 2010-03-25 |
AU2009291155A1 (en) | 2010-03-18 |
CA2736295A1 (en) | 2010-03-18 |
JP2012502887A (ja) | 2012-02-02 |
JP5701758B2 (ja) | 2015-04-15 |
KR20110063542A (ko) | 2011-06-10 |
NZ591073A (en) | 2012-11-30 |
AR073578A1 (es) | 2010-11-17 |
EA201100483A1 (ru) | 2011-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110931A1 (es) | Pirrolidin-2-onas como ligandos de hdm2 | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
EA201070544A1 (ru) | Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
CL2009000619A1 (es) | Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer. | |
UY31384A1 (es) | Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b | |
GEP201706703B (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
EA200601766A1 (ru) | Производные имидазола | |
CY1115262T1 (el) | Ανταγωνιστες trpv1 και χρησεις αυτων | |
PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
EA201101699A1 (ru) | Синергетические фунгицидные смеси | |
ATE473975T1 (de) | Chemische verbindungen | |
ATE398613T1 (de) | Chemische verbindungen | |
PE20090109A1 (es) | Compuestos pirrolicos como inhidores de la bomba de protones | |
PE20071114A1 (es) | Compuestos de tiazol como agentes moduladores de pkb | |
BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
ECSP067120A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
ECSP066991A (es) | 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
PE20090975A1 (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |